Anthropic today launched Claude Design, a new AI product for creating designs, prototypes, slides, and more. Claude Design ...

On the consumer side, sorghum is beginning to show up in formats that are familiar. It’s finding its way into household-name ...

New release introduces automated reporting and competitor analysis, alongside a roadmap toward SOC 2 Type I and II ...

Quantum computers, systems that process information leveraging quantum mechanical effects, could outperform classical computers on some advanced tasks. These systems rely on qubits, the fundamental ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

Claude can now generate visuals when producing a response. (Anthropic) With Claude enjoying a moment of newfound popularity among regular people, Anthropic is previewing an update designed to make its ...

Global X SuperDividend (DIV) yields 6.1%, Amplify Enhanced Dividend (DIVO) yields 6%+ with 73% five-year return, Global X Preferred (PFFD) yields 6.2%, SPDR High Yield Bond (SPHY) yields 6.7%. DIVO ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

I recently saw a tweet showing how Google has acquired companies over the years and built products around them. Here is the link to the tweet if you want. Now, Google made another announcement: Google ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...